For decades, neurology has viewed adult brain damage as a relatively permanent state, offering mostly compensatory therapies to help patients adapt to their deficits. But Episode 59 explores a 2026 systematic review by Leon-Rojas and Sacks-Zimmerman that flips the script: could subanesthetic ketamine actually act as a powerful cognitive enhancer?

We unpack the paradox of using a dissociative anesthetic to sharpen the mind. The secret lies in looking past the acute intoxication phase—the temporary “construction zone”—to the structural remodeling that follows. We explore ketamine’s two-phase neuroprotective mechanism: acting first as a “fire extinguisher” to block NMDA receptors and stop toxic glutamate floods (excitotoxicity), and second as “fertilizer” by releasing BDNF to sprout new neural bridges (synaptogenesis).

While animal models show a staggering 93.2% success rate in restoring cognitive functions like working memory and spatial learning, the review’s single human study on Huntington’s disease showed short-term cognitive impairment. We discuss why timing and context are everything: to truly harness this drug, the biological “window of neuroplasticity” must be actively paired with rigorous, targeted neurorehabilitation to guide the brain’s rewiring.

Reference:

Leon-Rojas, J. E., Mascialino, G., Vinueza Mera, L., Hinojosa-Figueroa, M. S., Navas Arias, C. F., Cadena Barberis, E. D., & Sacks-Zimmerman, A. (2026). Ketamine as a potential cognitive enhancer in neurological disorders: Evidence from preclinical and clinical studies. Frontiers in Neurology, 17, 1786249. https://doi.org/10.3389/fneur.2026.1786249

The post Ketamine, the Cognitive Enhancer appeared first on Talking Ketamine Podcast.